Skip to content
  • IFPMA Twitter
  • IFPMA LinkedIn
  • IFPMA Youtube
  • IFPMA Slideshare
  • IFPMA Flickr
  • IFPMA RSS
IFPMA
  • Who We Are
    • IFPMA in Brief
    • Our Governance and Leadership
    • Our Membership
      • Full Members
        • Associations
        • Companies
      • Affiliate Members
    • Our Experts
    • Join Us
  • Topics
  • News Center
    • News Releases
    • Blog
      • Global Health Matters
      • Science Matters
      • DG’s Column
    • Statements
    • Latest News from Our Members
  • Resources
    • Publications
      • News Releases
      • Statements
      • Position Papers
      • Publications
      • External Studies
      • Infographics
      • Event Highlights
    • Multimedia
      • Interviews
      • Videos
      • Slides
    • IFPMA Interactive Platforms
      • IFPMA COVID-19 Hub
      • Global Health Progress
      • 50 Years of Global Health Progress
  • Events
    • Upcoming IFPMA Events
      • Geneva Pharma Forums
      • Assemblies
      • Other IFPMA Events
      • IFPMA in External Events
      • IFPMA Press Briefings
    • Past IFPMA Events
      • Geneva Pharma Forums
      • Assemblies
      • Other IFPMA Events
      • IFPMA in External Events
      • IFPMA Press Briefings
  • Partners
  • BCR
  • Inventing Medicines and Vaccines
  • Strengthening Regulatory Systems
  • Ethics and Business Integrity
  • Boosting Innovation and Access
  • Tackling Global health challenges
Climate change Economic footprint IP Sustainable innovation Value of innovation

spotlight

Value of innovation

Inventing Medicines and Vaccines
African Medicines Agency Biosimilars Biotherapeutic medicines Falsified medicines Import testing Pharmacovigiliance Quality, safety, and efficacy Regulatory conferences Regulatory system strengthening / Harmonization Supply chain The Africa Regulatory Network (ARN) The ARN: Le réseau africain de réglementation pharmaceutique

spotlight

Pharmacovigiliance

Strengthening Regulatory Systems
IFPMA Code of Practice (2019) Our Ethos in Action Our Ethos Code eLearning Tool IFPMA Notes for Guidance IFPMA Complaint Operating Procedure How to File a Code Complaint Complaint Submission Form Cases Business Ethics for APEC SMEs Initiative Consensus Framework for Ethical Collaboration

spotlight

IFPMA Code of Practice (2019)

Ethics and Business Integrity
Access to medicines Global Policy Principles on Digital Health Health technology assessment IP Technology Transfer Trade

spotlight

Access to medicines

Boosting Innovation and Access
Ageing Antimicrobial resistance Cancer Child and maternal health Diabetes Do you mind? campaign Ebola Falsified medicines Health partnerships HIV/AIDS Humanitarian and disaster relief aid Influenza Malaria Mental and neurological disorders Neglected tropical diseases Non-communicable diseases Novel Coronavirus (COVID-19) Pandemic Preparedness Psoriasis Public health implications of the implementation of the Nagoya Protocol Rare diseases Supply chain Sustainable development goals Tuberculosis Universal Health Coverage Vaccination confidence Vaccines innovation Vaccines protect communities Vaccines sustainability Value of immunization Viral hepatitis Workplace wellness Zika Virus

spotlight

Universal Health Coverage

Tackling Global health challenges
  • Home
  • >
  • Resources
  • >
  • External Studies
  • >
  • Counterfeit drug penetration into global legitimate medicine supply chains: A global assessment

Counterfeit drug penetration into global legitimate medicine supply chains: A global assessment

Published on: 20 April 2015

Cover_Counterfeit_Drug_Penetration

Downloads

» AJTMH_Counterfeit Drug Penetration into Global Legitimate Medicine Supply Chains_April2015

Resources

1. Counterfeit medicines in legitimate supply chains, A study by University of California, San Diego School of Medicine & the Pharmaceutical Security Institute (PSI)
Infographics

Infographics

1. Counterfeit medicines in legitimate supply chains, A study by University of California, San Diego School of Medicine & the Pharmaceutical Security Institute (PSI)

World Health Assembly on counterfeits
Statements

Statements

World Health Assembly on counterfeits

Counterfeit medicines in legitimate supply chains SDCP & PSI Study
Infographics

Infographics

Counterfeit medicines in legitimate supply chains SDCP & PSI Study

Global pharmaceutical associations welcome MEDICRIME convention, landmark tool to curb global medicines counterfeiting
News Releases

News Releases

Global pharmaceutical associations welcome MEDICRIME convention, landmark tool to curb global medicines counterfeiting

IFPMA’s 10 principles on counterfeit medicines
Infographics

Infographics

IFPMA’s 10 principles on counterfeit medicines

WHA 68, Item 17.3, Substandard/spurious/falsely-labelled/falsified/counterfeit medical products
Statements

Statements

WHA 68, Item 17.3, Substandard/spurious/falsely-labelled/falsified/counterfeit medical products

Related Blog Entries

Making Progress in Fighting Counterfeit Drugs in Africa

Making Progress in Fighting Counterfeit Drugs in Africa

Traffic in Counterfeit Medicines Must be Curbed through International Cooperation and Regulatory Harmonization

Traffic in Counterfeit Medicines Must be Curbed through International Cooperation and Regulatory Harmonization

Related Topics

Supply chain
Falsified medicines

Tags

  • Counterfeit Medicines
  • Counterfeiting
  • Counterfeits
  • Global systems
  • Supply Chains
IFPMA

Chemin des Mines 9
1202 Geneva
Switzerland

+41 22 338 32 00
info@ifpma.org

  • File a Code Complaint
  • Privacy Policy
  • Terms of Use
  • Access to Our Extranet
  • Careers
  • Contact Us
  • IFPMA Twitter
  • IFPMA LinkedIn
  • IFPMA Youtube
  • IFPMA Slideshare
  • IFPMA Flickr
  • IFPMA RSS
Designed and Produced by ACW
^ Back to Top